^
    Back
    Association details:
    Biomarker:TMB-H
    Cancer:Biliary Tract Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    03/10/2023
    Excerpt:
    Biliary Tract Cancer….Primary Treatment for Unresectable and Metastatic Disease….Nivolumab + ipilimumab was added as a category 2B recommendation for TMB-H tumors